Long-Term Efficacy and Safety of Lorlatinib vs Alectinib in Patients With and Without Brain/Central Nervous System Metastases: Matching-Adjusted Indirect Comparisons
Mazieres J,Bauer T,Abrahami D,Polli A,Chu H,Ramachandran P,Chandler C,Tan M,Truscott J,Garcia CA
ELCC 2025
- 欧洲肺癌大会 2025
| 肿瘤 | 肺癌
Efficacy and Safety of Lorlatinib in Patients With ALK+ Metastatic Non-Small Cell Lung Cancer Previously Treated With an ALK Inhibitor: Results From a Phase 4 Study
Mazieres J,Bauer T,Abrahami D,Polli A,Chu H,Ramachandran P,Chandler C,Tan M,Truscott J,Garcia CA,Bearz A,Ricciardi S,Raut NV,Dols MC,Thungappa SC,Sacco PC,Thurm H,Pavlov D,Toffalorio F,Felip E
ELCC 2025
- 欧洲肺癌大会 2025
| 肿瘤 | 肺癌 | 博瑞纳
Real-World Treatment Sequencing and Outcomes in ALK-Positive Advanced Non-Small Cell Lung Cancer
Dietrich M, Zala D, Abrahami D, Patel A, Assayag J, Patel A, Benjumea D, Rava A, Crowley A, Kent M, Tsang C
ELCC 2025
- 欧洲肺癌大会 2025
| 肿瘤 | 肺癌 | 博瑞纳
